Short Courses*

Monday, September 23 | 12:00 – 3:00 pm


New Class of Kinase Inhibitors: Covalent Modifiers

Instructors: Alan Corin, Ph.D., Senior Director, Biochemistry and Molecular Pharmacology, Celgene Avilomics Research

Eric Schwartz, Ph.D., Senior Director, Chemistry, Celgene Avilomics Research

Interest in covalent kinase inhibitors as potential drug candidates is steadily increasing and there is a growing body of data showing both efficacy and safety in patients. Covalent inhibitors offer a means of obtaining optimal target engagement with excellent selectivity and a prolonged duration of action. This workshop will cover practical and theoretical considerations for designing selective covalent kinase inhibitors, as well as considerations for testing schemes to examine on- and off-target activities.

Practical Aspects of Structure-Based Drug Discovery with GPCRs

Instructors: Michael Hanson, Ph.D., Director, Structural Biology, Receptos

Christopher Tate, Ph.D., Professor, Laboratory of Molecular Biology, MRC, United Kingdom

This course will explore the changes in rational drug design approaches for GPCRs in light of the new structural knowledge now available from the many new GPCR crystal structures. Questions such as quality of crystal data, expected throughput and turnaround times and impact on modeling activities will be explored.

Biochemical and Structure-Based Approaches to Epigenetic Drug Discovery

Instructors: Zhaohui Sunny Zhou, Ph.D., Faculty Fellow, Barnett Institute of Chemical and Biological Analysis; Associate Professor, Department of Chemistry and Chemical Biology, Northeastern University

David Sheppard, Ph.D., Director, Computational Chemistry, BioFocus

Additional Instructors to be Announced


Monday, September 23 | 3:30 – 6:30 pm


Allosteric Modulators of GPCRs

Instructors: Corey Hopkins, Ph.D., Research Assistant Professor, Pharmacology, Vanderbilt University

Stephan Schann, Ph.D., Head, Research, Domain Therapeutics SA

Allosteric modulators represent a novel paradigm to therapeutically target G-protein-coupled receptors (GPCRs). However, their identification and characterization using standard functional assays remain elusive due to the‘context-dependent phenomena’. This course will discuss important aspects of hit identification and validation of allosteric modulators in GPCR research activity.

 


Advancing Tools and Technologies for Fragment-Based Design

Instructors: Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.

Edward R. Zartler, Ph.D., President & CSO, Quantum Tessera Consulting

This course aims to introduce the fundamentals of Fragment-based Lead Discovery (FBLD) to attendees. The first section will focus on the concepts of using fragments for hit generation. Special emphasis will be placed on practical pitfalls and the many ways to advance fragments to leads and drugs. The second part of the course will discuss the variety of fragment screening methods and when they are best applied. The composition of fragment libraries will also be discussed in detail. The attendees should come away from this course with a solid understanding of what FBLD is and how to apply it.

Setting Up Effective RNAi Screens: Getting From Design to Data

The course is designed to provide in-depth information on how to go about setting up RNAi screening experiments and how to design assays for getting optimal results. The challenges working with siRNAs and shRNAs and the delivery reagents needed to get them into the appropriate cells and tissues will be discussed. The instructors will also provide their input on best practices for the execution of experiments and interpretation of results when dealing with complex biology and informatics.

Instructors:

Caroline Shamu, Ph.D., Director, ICCB-Longwood Screening Facility, Harvard Medical School

Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health

John Doench, Ph.D., Research Scientist, Broad Institute of Harvard and MIT

Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Institutes for Health


Production and Presentation of Integral Membrane Proteins for Antibody Discovery

Small molecule pharmaceuticals can exhibit remarkable target specificity. Nevertheless, the exquisite selectivity towards the desired subtype of an ion channel or GPCR is often elusive, resulting in undesirable effects on closely related variants. Antibodies hold promise of even greater specificity, and are proven to be effective therapeutics targeting certain membrane proteins. Yet none of the current targets for approved antibodies is either a GPCR or an ion channel. There are two main reasons: First, the difficulties involved in the effective presentation of integral membrane proteins for antibody generation-selection. Second, the area and energetics of Ab binding interactions can cause unwanted conformational changes of the antibody-bound GPCR or channel, which may lead to only agonist or only antagonist binders.

Instructor: David Bramhill, Ph.D., Principal, Bramhill Biological Consulting, LLC


Characterization and Quantification of Histone Modifications

Until recently, standardized high-throughput methods for characterizing and quantifying post-translational histone modifications have been challenging. Now, with the application of advanced methods utilizing modification specific antibodies and high resolution mass spectrometry, various strategies have been developed for precise in vivo monitoring and profiling of histones, their variants, reader proteins, the combinatorial histone code, and the overarching chromatin landscape in multiple cellular states. This workshop is designed to provide a tutorial on utilizing what is becoming the gold standard for histone post-translational modification analysis.

Instructors:

Alan Tackett, Ph.D., Associate Professor, Director UAMS Proteomics Facility, University of Arkansas for Medical Sciences

Sean Taverna, Ph.D., Assistant professor, Pharmacology & Molecular Sciences, IBBS Center for Epigenetics, Johns Hopkins University School of Medicine

Additional Instructors to be Announced


Wednesday, September 25 | 6:45 – 9:30 pm | Dinner will be provided


Setting Up Effective Functional Screens Using 3D Cell Cultures

The course is designed to provide in-depth information on how to go about setting up low and high-throughput screening experiments using 3D cell cultures. The challenges working with 3D cell cultures, from experimental design to data analysis will be discussed. The instructors will also share their experiences on how they tested and evaluated various cell culture reagents and growth matrices, what worked and what didn’t and what you need to consider when setting up similar screens in your lab.

Instructors:

Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Lesley Matthews, Ph.D., Research Scientist, Biomolecular Screening and Profiling/Probe Development Group, National Center for Advancing Translational Sciences, NIH

Additional Instructors to be Announced


Tools for Detection and Utilization of Epigenetic Markers

Instructors:

Pamela Munster, M.D., Associate Professor, Department of Medicine, University of California San Francisco

Sophie Lelièvre, D.V.M., LL.M., Ph.D., Associate Professor, Department of Basic Medical Sciences; Associate Director, Discovery Groups, NCI-Designated Purdue Center for Cancer Research, Purdue University

Yingming Zhao, Ph.D., Professor, The Ben May Department for Cancer Research, University of Chicago


*Separate Registration Required for Short Courses